BICARA THERAPEUTICS INC
BCAXNASDAQTrading Snapshot
- Day Range
- $18.36 – $18.72
- 52-Week Range
- $13.59 – $30.99
- Volume
- $2.24B
- Avg Volume
- $1.57B
- Shares Outstanding
- 65.7M
- Next Earnings
- Oct 31, 2026
Fundamentals Snapshot
- Annual Revenue
- $120M
- Last Q Revenue
- $30M
- P/E Ratio
- -6.0
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-2.73
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +1.3%
Why Investors Own BCAX
- ✓High-growth profile — revenue up +7.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 68% gross margin and 18% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
BICARA THERAPEUTICS INC
BCAX
StockOtter · stockotter.spaceAbout BICARA THERAPEUTICS INC
Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, to
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, tod
Dimensional Fund Advisors LP Increases Stock Position in Bicara Therapeutics Inc. $BCAX
Dimensional Fund Advisors LP grew its holdings in Bicara Therapeutics Inc. (NASDAQ: BCAX) by 166.9% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (
Bicara Therapeutics: My Optimism Is Building Despite Recent Market Headwinds
Bicara Therapeutics (BCAX) is upgraded to 'Buy' on favorable early clinical signals for ficerafusp alfa in head and neck cancer. BCAX's phase 1 data show promising median overall survival, but toxicity and small cohort s
Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results
Bicara Therapeutics Inc (NASDAQ:BCAX) reported a narrower-than-expected loss for the second quarter on Tuesday.
Bicara Therapeutics Inc. (BCAX) Q2 2026 Earnings Call Transcript
Bicara Therapeutics Inc. (BCAX) Q2 2026 Earnings Call Transcript